Ioannis Xynos

6.3k total citations · 4 hit papers
44 papers, 4.0k citations indexed

About

Ioannis Xynos is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ioannis Xynos has authored 44 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Surgery and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ioannis Xynos's work include Esophageal Cancer Research and Treatment (9 papers), Gastric Cancer Management and Outcomes (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ioannis Xynos is often cited by papers focused on Esophageal Cancer Research and Treatment (9 papers), Gastric Cancer Management and Outcomes (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ioannis Xynos collaborates with scholars based in United Kingdom, Japan and United States. Ioannis Xynos's co-authors include Lee Buttery, Larry L. Hench, Alasdair J. Edgar, Julia M. Polak, J. M. Polak, Mika Hukkanen, J. Batten, Yuko Kitagawa, Yuichiro� Doki and Ken Kato and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Ioannis Xynos

41 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass� 45S5 dissolution

2001 969 citations Ioannis Xynos, Alasdair J. Edgar et al. Journal of Biomedical Materials Research profile →
Ionic Products of Bioactive Glass Dissolution Increase Proliferation of Human Osteoblasts and Induce Insulin-like Growth Factor II mRNA Expression and Protein Synthesis

2000 787 citations Ioannis Xynos, Alasdair J. Edgar et al. Biochemical and Biophysical Research Communications profile →
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

2019 751 citations Ken Kato, Byoung Chul Cho et al. The Lancet Oncology profile →
Bioglass ®45S5 Stimulates Osteoblast Turnover and Enhances Bone Formation In Vitro: Implications and Applications for Bone Tissue Engineering

2000 563 citations Ioannis Xynos, Mika Hukkanen et al. Calcified Tissue International profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ioannis Xynos United Kingdom	18	2.3k	1.5k	1.1k	847	596	44	4.0k
Jörg Handschel Germany	29	1.2k 0.5×	1.0k 0.7×	1.1k 1.0×	279 0.3×	289 0.5×	97	3.5k
Craig D. Friedman United States	30	1.4k 0.6×	2.1k 1.4×	1.2k 1.0×	351 0.4×	289 0.5×	73	3.9k
Tara Aghaloo United States	47	2.0k 0.9×	1.3k 0.9×	2.1k 1.8×	3.7k 4.4×	906 1.5×	150	9.5k
Akira Myoui Japan	40	1.5k 0.7×	1.3k 0.8×	617 0.5×	1.2k 1.4×	478 0.8×	147	5.5k
Martin Gosau Germany	31	696 0.3×	1.0k 0.7×	1.0k 0.9×	424 0.5×	290 0.5×	168	3.2k
Cody Bünger Denmark	46	2.5k 1.1×	4.2k 2.8×	663 0.6×	412 0.5×	633 1.1×	208	7.2k
Frank Kloss Austria	30	1.6k 0.7×	1.3k 0.9×	1.5k 1.3×	215 0.3×	326 0.5×	75	4.0k
Alan W. Yasko United States	44	1.9k 0.8×	2.3k 1.5×	603 0.5×	1.1k 1.3×	1.2k 2.0×	91	6.1k
Izumi Asahina Japan	32	1.1k 0.5×	888 0.6×	854 0.7×	430 0.5×	239 0.4×	184	3.3k
Masaru Murata Japan	26	1.4k 0.6×	715 0.5×	1.1k 1.0×	337 0.4×	274 0.5×	136	3.7k

Countries citing papers authored by Ioannis Xynos

Since Specialization

Citations

This map shows the geographic impact of Ioannis Xynos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ioannis Xynos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ioannis Xynos more than expected).

Fields of papers citing papers by Ioannis Xynos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ioannis Xynos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ioannis Xynos. The network helps show where Ioannis Xynos may publish in the future.

Co-authorship network of co-authors of Ioannis Xynos

This figure shows the co-authorship network connecting the top 25 collaborators of Ioannis Xynos. A scholar is included among the top collaborators of Ioannis Xynos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ioannis Xynos. Ioannis Xynos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Al-Batran, S-E., Zev A. Wainberg, Woo Jin Hyung, et al.. (2025). LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma. Annals of Oncology. 36. S1623–S1624.

Oh, Do‐Youn, Aiwu Ruth He, Shukui Qin, et al.. (2025). Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. Journal of Hepatology. 83(5). 1092–1101. 5 indexed citations

He, Aiwu Ruth, Shukui Qin, L-T. Chen, et al.. (2024). 55P Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC). Annals of Oncology. 35. S233–S234.

Chan, Stephen L., Bruno Sangro, Masatoshi Kudo, et al.. (2024). Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4122–4122. 4 indexed citations

Kudo, Masatoshi, Stephen L. Chan, Bruno Sangro, et al.. (2024). Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 42(23_suppl). 65–65. 1 indexed citations

Oh, D-Y., Yelena Y. Janjigian, S-E. Al-Batran, et al.. (2023). 129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Annals of Oncology. 34. S1520–S1521. 5 indexed citations

Hench, Larry L., et al.. (2020). Gene activating glasses. Physics and Chemistry of Glasses European Journal of Glass Science and Technology Part B. 61(4). 155–162. 3 indexed citations

Thuss‐Patience, Peter, Byoung Chul Cho, Ken Kato, et al.. (2020). Nivolumab versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC): The Phase 3 attraction-3 Study. University of Southern Denmark Research Portal (University of Southern Denmark). 43. 1 indexed citations

Basset‐Séguin, Nicole, Axel Hauschild, Jean‐Jacques Grob, et al.. (2015). Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. The Lancet Oncology. 16(6). 729–736. 170 indexed citations

10.

Xynos, Ioannis, et al.. (2013). Chemotherapy ± Cetuximab Modulates Peripheral Immune Responses in Metastatic Colorectal Cancer. Oncology. 84(5). 273–283. 11 indexed citations

11.

Michailidou, Despina, et al.. (2013). Modulation of peripheral immune responses by paclitaxel–ifosfamide–cisplatin chemotherapy in advanced non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology. 139(12). 1995–2003. 8 indexed citations

12.

Syrios, John, Stavros Sougioultzis, Ioannis Xynos, et al.. (2012). Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter Pyloriinfection. BMC Cancer. 12(1). 264–264. 21 indexed citations

13.

Sougioultzis, Stavros, John Syrios, Ioannis Xynos, et al.. (2011). Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: A retrospective analysis. European Journal of Surgical Oncology. 37(4). 312–318. 42 indexed citations

14.

Tsiakalos, Aristotelis, Ioannis Xynos, Nikolaos V. Sipsas, & Gregory Kaltsas. (2010). Pituitary Insufficiency after Infectious Meningitis: A Prospective Study. The Journal of Clinical Endocrinology & Metabolism. 95(7). 3277–3281. 28 indexed citations

15.

Xynos, Ioannis, et al.. (2009). Extended fungal skin infection due toAureobasidium pullulans. Clinical and Experimental Dermatology. 34(8). e892–e894. 10 indexed citations

16.

Xynos, Ioannis, et al.. (2009). Hypercalcemia in a patient with cholangiocarcinoma: a case report. International Archives of Medicine. 2(1). 35–35. 5 indexed citations

17.

Xynos, Ioannis, Alasdair J. Edgar, Lee Buttery, Larry L. Hench, & Julia M. Polak. (2001). Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass� 45S5 dissolution. Journal of Biomedical Materials Research. 55(2). 151–157. 969 indexed citations breakdown →

18.

Xynos, Ioannis, Alasdair J. Edgar, Lee Buttery, Larry L. Hench, & Julia M. Polak. (2000). Ionic Products of Bioactive Glass Dissolution Increase Proliferation of Human Osteoblasts and Induce Insulin-like Growth Factor II mRNA Expression and Protein Synthesis. Biochemical and Biophysical Research Communications. 276(2). 461–465. 787 indexed citations breakdown →

19.

Xynos, Ioannis, Mika Hukkanen, J. Batten, et al.. (2000). Bioglass ®45S5 Stimulates Osteoblast Turnover and Enhances Bone Formation In Vitro: Implications and Applications for Bone Tissue Engineering. Calcified Tissue International. 67(4). 321–329. 563 indexed citations breakdown →

20.

Polgár, Beáta, Alíz Barakonyi, Ioannis Xynos, & Júlia Szekeres‐Barthó. (1999). The Role of γ/δ T Cell Receptor Positive Cells in Pregnancy. American Journal of Reproductive Immunology. 41(4). 239–244. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact